B
Biocorp
Innovative medical devices for pharmaceutical companies
About Biocorp
BIOCORP Production specializes in the development and manufacturing of smart medical devices, particularly focusing on diabetes management solutions. The company operates in the healthcare and medical technology market, serving clients such as pharmaceutical companies, healthcare providers, and patients. BIOCORP's business model revolves around the creation of innovative products like smart caps for disposable insulin pens, which have received FDA clearance, ensuring they meet stringent regulatory standards. Revenue is generated through the sale of these advanced medical devices and through strategic partnerships, such as the recent acquisition of a controlling stake by Novo Nordisk. This acquisition highlights BIOCORP's strong market position and potential for growth. The company is committed to data security and environmental sustainability, as evidenced by their initiatives and compliance with data protection regulations.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2004
- Headquarters
- Le Broc, France
- Listing
- IPO 2015
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
The Vatel Direct
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Biocorp on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biocorp on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.